FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for GlioblastomaBusiness Wire • 11/21/24
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer PatientsBenzinga • 10/16/24
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?Zacks Investment Research • 10/16/24
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer TreatmentInvestors Business Daily • 10/15/24
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung CancerBusiness Wire • 10/15/24
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) TherapyBusiness Wire • 09/09/24
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a BetZacks Investment Research • 08/16/24
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung CancerBusiness Wire • 08/14/24
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to TradeZacks Investment Research • 07/30/24
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free SurvivalBusiness Wire • 06/03/24
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in GermanyBusiness Wire • 05/23/24